SANTA MONICA, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that Arie Belldegrun, MD, FACS, President and Chief Executive Officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 12:00 PM Pacific Time. The event will be held in San Francisco at the Westin St. Francis Hotel. In addition, members of the Kite management team will participate in the Sanford C. Bernstein "Rising Stars Breakfast" on Tuesday, January 13, 2015 in San Francisco.
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com.
CONTACT: Kite Contacts:
Cynthia M. Butitta
Chief Financial Officer and Chief Operating Officer
310-824-9999
For Media: Justin Jackson
For Investor Inquiries: Nancy YuBurns McClellan
(212) 213-0006
jjackson@burnsmc.comnyu@burnsmc.comKite Pharma, Inc.News Provided by Acquire Media
